Cantor Fitzgerald raised the firm’s price target on InflaRx (IFRX) to $8 from $3 and keeps an Overweight rating on the shares. InflaRx’s C5aR inhibitor is looking good, and the company should pursue the efficacy signal in a larger, longer Phase 2B hidradenitis suppurative study, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx price target raised to $9 from $2 at Raymond James
- InflaRx price target raised to $7 from $3 at Oppenheimer
- InflaRx price target raised to $24 from $3 at Lucid Capital
- Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive Optimism
- InflaRx price target raised to $22 from $10 at Guggenheim